• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Sab Biotherapeutics Inc (NQ: SABS )

    3.100 -0.600 (-16.22%)
    Streaming Delayed Price Updated: 3:59 PM EST, Nov 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Sab Biotherapeutics Inc

    < Previous 1 2 Next >
    SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB BIO Appoints Lucy To as Chief Financial Officer
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAb Biotherapeutics Rebrands as SAB BIO
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics Announces Departure of Chief Financial Officer
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
    This regulatory clearance enables clinical development of SAB-142 in patients with type 1 diabetes in the US 
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics Provides SAB-142 Trial Update
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics to Present at INNODIA Annual Meeting
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics Announces Executive Leadership Change
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer
    Finance leader joins SAB with more than 25 years of experience as a leading biotech equity research analyst 
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.